Published in

Society of Nuclear Medicine, Journal of Nuclear Medicine, 3(53), p. 363-370, 2012

DOI: 10.2967/jnumed.111.098319

Links

Tools

Export citation

Search in Google Scholar

Assessment of Progesterone Receptors in Breast Carcinoma by PET with 21-<sup>18</sup>F-Fluoro-16α,17α-[(R)-(1′-α-furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione

Journal article published in 2012 by Farrokh Dehdashti, Richard Laforest, Feng Gao, Rebecca L. Aft, Carmen S. Dence, Dong Zhou, Kooresh I. Shoghi ORCID, Barry A. Siegel, John A. Katzenellenbogen, Michael J. Welch
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
  • If required by funding agency
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

This first-in-human study was designed to evaluate the safety and dosimetry of the progesterone analog 21-18F-fluoro-16α,17α-[(R)-(1′-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione (18F-FFNP), as well the feasibility of imaging tumor progesterone receptors (PRs) by PET in breast cancer.